Biopharma & Life Sciences
Pfizer Executive Compensation (FY25)
PFE · New York, NY · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): April 27, 2026
406 figures on this page: 400 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Albert Bourla was paid $27,585,301 in total compensation as Chairman and Chief Executive Officer for fiscal 2025, and compared with the $24,648,727 reported for fiscal 2024, Bourla's total was 11.9% higher. The disclosed chief executive pay ratio for fiscal 2025 is 277:1, against median employee compensation of $99,631. For fiscal 2025, shareholders backed the say-on-pay proposal with 88.0% of votes cast for or against in favor at the meeting held April 23, 2026. The disclosed peer group includes 3M Company, Abbott Laboratories, Caterpillar Inc., Chevron Corporation and Comcast Corporation, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Albert Bourla: $24,648,727 → $27,585,301 (11.9% higher)
Say-on-pay support: 54.7% → 88.0% (33.3 points higher)
CEO pay ratio: 269:1 → 277:1 (3.0% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Pfizer's chief executive and what were they paid?
Albert Bourla was paid $27,585,301 in total compensation as Chairman and Chief Executive Officer for fiscal 2025. Compared with the $24,648,727 reported for fiscal 2024, Bourla's total was 11.9% higher.
What was Pfizer's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 88.0% of votes cast for or against in favor at the meeting held April 23, 2026.
Which companies are in Pfizer's peer group?
The disclosed peer group includes 3M Company, Abbott Laboratories, Caterpillar Inc., Chevron Corporation and Comcast Corporation, among others. The Pharmaceutical Peers names AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company and Eli Lilly and Company, among others.
What is Pfizer's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 277:1, against median employee compensation of $99,631.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Albert Bourla Chairman and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
David Denton Chief Financial Officer, Executive Vice President | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mikael Dolsten Chief Scientific Officer, President, Pfizer Research & Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Angela Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Albert Bourla Chairman and Chief Executive Officer | ◇ | — | ◇ | ◇ | — | ◇ | ◇ | ◇ |
Mikael Dolsten Chief Scientific Officer, President, Pfizer Research & Development | ◇ | — | ◇ | ◇ | — | ◇ | ◇ | ◇ |
Angela Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business Departed during or after this year | ◇ | — | ◇ | ◇ | — | ◇ | ◇ | ◇ |
William Pao Former Chief Development Officer, Executive Vice President Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Douglas Lankler Chief Legal Officer, Executive Vice President | ◇ | — | ◇ | ◇ | — | ◇ | ◇ | ◇ |
Aamir Malik Chief U.S. Commercial Officer, Executive Vice President | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
David Denton Chief Financial Officer, Executive Vice President | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Albert Bourla Chairman and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mikael Dolsten Chief Scientific Officer, President, Pfizer Research & Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Aamir Malik Chief U.S. Commercial Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
David Denton Chief Financial Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Chris Boshoff Chief Scientific Officer and President, Research & Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Lankler Chief Legal Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Albert Bourla Chairman and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Chris Boshoff Chief Scientific Officer and President, Research & Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
David Denton Chief Financial Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Aamir Malik Chief U.S. Commercial Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Lankler Chief Legal Officer, Executive Vice President | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Aamir Malik | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
| Aamir Malik | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Albert Bourla | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
| Albert Bourla | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Chris Boshoff | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Chris Boshoff | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
| Chris Boshoff | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
| David Denton | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| David Denton | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
| Douglas Lankler | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Douglas Lankler | PSU | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Douglas Lankler | Option | ◇ | — | ◇ | 2/28/2029 |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/25/2026 | |
| Option | ◇ | — | ◇ | 2/27/2031 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| Option | ◇ | — | ◇ | 2/28/2029 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2029 | |
| Option | ◇ | — | ◇ | 2/27/2027 | |
| Option | ◇ | — | ◇ | 2/28/2026 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| Option | ◇ | — | ◇ | 2/25/2028 | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| Option | ◇ | — | ◇ | 3/4/2030 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| David Denton | Option | ◇ | — | ◇ | 3/4/2030 |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2029 | |
| Option | ◇ | — | ◇ | 5/31/2029 | |
| Option | ◇ | — | ◇ | 5/31/2029 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2031 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| PSU | ◇ | ◇ | — | — | |
| Albert Bourla | Option | ◇ | — | ◇ | 2/25/2028 |
| Option | ◇ | — | ◇ | 2/25/2026 | |
| Option | ◇ | — | ◇ | 3/4/2030 | |
| Option | ◇ | — | ◇ | 2/27/2029 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| Option | ◇ | — | ◇ | 2/28/2026 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2027 | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| Option | ◇ | — | ◇ | 2/27/2031 | |
| PSU | ◇ | ◇ | — | — | |
| Chris Boshoff | Option | ◇ | — | ◇ | 2/27/2029 |
| Option | ◇ | — | ◇ | 2/25/2028 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| Option | ◇ | — | ◇ | 2/27/2027 | |
| Option | ◇ | — | ◇ | 2/28/2026 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2031 | |
| Option | ◇ | — | ◇ | 3/4/2030 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Aamir Malik | Option | ◇ | — | ◇ | 3/4/2030 |
| Option | ◇ | — | ◇ | 2/27/2031 | |
| Option | ◇ | — | ◇ | 2/23/2030 | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/2029 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2029 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/23/2030 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Shantanu Narayen Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Suzanne Nora Johnson | ◇ | ◇ | — | — | — | ◇ | ◇ |
Joseph J. Echevarria | ◇ | ◇ | — | — | — | ◇ | ◇ |
Scott Gottlieb | ◇ | ◇ | — | — | — | ◇ | ◇ |
James C. Smith | ◇ | ◇ | — | — | — | — | ◇ |
Susan Desmond-Hellmann | ◇ | ◇ | — | — | — | — | ◇ |
Cyrus Taraporevala | ◇ | ◇ | — | — | — | ◇ | ◇ |
James Quincey | ◇ | ◇ | — | — | — | ◇ | ◇ |
Dan R. Littman | ◇ | ◇ | — | — | — | ◇ | ◇ |
Susan Hockfield | ◇ | ◇ | — | — | — | ◇ | ◇ |
Ronald E. Blaylock | ◇ | ◇ | — | — | — | — | ◇ |
Mortimer J. Buckley | ◇ | ◇ | — | — | — | — | ◇ |
Helen H. Hobbs | ◇ | — | — | — | — | — | ◇ |
Albert Bourla served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
Equity is delivered as Pfizer Stock Units.
Stock ownership guideline: 5x annual cash retainer ($775,000)
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 3M Company MMM
- Abbott Laboratories ABT
- Caterpillar Inc. CAT
- Chevron Corporation CVX
- Comcast Corporation CMCSA
- ConocoPhillips COP
- Danaher Corporation DHR
- Honeywell International Inc. HON
- International Business Machines Corporation IBM
- Lockheed Martin Corporation LMT
- Medtronic plc MDT
- Mondelez International, Inc. MDLZ
- PepsiCo, Inc. PEP
- RTX Corporation RTX
- The Boeing Company BA
- The Coca-Cola Company KO
- The Procter & Gamble Company PG
- Thermo Fisher Scientific Inc. TMO
- United Parcel Service, Inc. UPS
- Verizon Communications Inc. VZ
Pharmaceutical Peers
- AbbVie Inc. ABBV
- Amgen Inc. AMGN
- AstraZeneca PLC AZN
- Bristol-Myers Squibb Company BMY
- Eli Lilly and Company LLY
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Johnson & Johnson JNJ
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Roche Holding AG symbol not shown
- Sanofi SNY
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | April 23, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | April 24, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | April 25, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | April 27, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | April 28, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | April 22, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Pfizer disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pfizer sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
406 figures on this page: 400 cited to the filing that reported them, 6 calculated from figures it prints.
400 cited to the filing
6 calculated from the filing
Documents cited
- 0000078003-26-000044Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000078003-26-0000332025 Director Compensation Table · 2025 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE · CEO PAY RATIO · Compensation Tables · and 3 more sections
- 0000078003-25-000109Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000078003-25-000062Compensation Tables · SUMMARY COMPENSATION TABLE · Summary Compensation Table
- 0000078003-24-000101Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000078003-24-000068Compensation Tables · SUMMARY COMPENSATION TABLE
- 0001628280-23-014368Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000078003-23-000040Summary Compensation Table
- 0000078003-22-000066Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000078003-21-000059Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pfizer executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PFE (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pfizer and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Pfizer discloses
The companies named in PFE's own disclosed peer group.
3M CompanyAbbott LaboratoriesCaterpillar Inc.Chevron CorporationHoneywell International Inc.International Business Machines CorporationMedtronic plcThe Boeing CompanyThe Coca-Cola CompanyThe Procter & Gamble CompanyAbbVie Inc.Amgen Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences, Inc.Johnson & JohnsonMerck & Co., Inc.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}